Fig 1: Representative immunohistochemical staining characteristics of CLEC1B and PD-L1 expression in four HCC patients.(A, B) HCC with low CLEC1B and high PD-L1 expression. (C, D) HCC with high CLEC1B and low PD-L1 expression. (E, F) HCC with low CLEC1B and PD-L1 expression. (G, H) HCC with high CLEC1B and PD-L1 expression.
Fig 2: CLEC1B mRNA level is significantly reduced in tumors of LIHC and associated with poor clinical outcome.(A) Differential expression of CLEC1B between tumor and adjacent normal tissues from various types of cancer. Data are extracted from TIMER web server. ***P < .001. (B) Kaplan-Meier analysis of OS and DFS stratified by CLEC1B. Data are generated from GEPIA web server. Abbreviation: LIHC, liver hepatocellular carcinoma.
Fig 3: Decreased expression of CLEC1B mRNA is related to high risk of TH.(A) Representative gross specimens of HCC with/without TH. (B) CLEC1B expression in NT, TH-negative tumor, and TH-positive tumor. **P < .01. ***P < .001. Abbreviation: NT, nontumor tissues.
Supplier Page from Abcam for Anti-CLEC-2 antibody